Evidence map›Paper›PMID 39748899›Full record

ReviewInternational journal of nanomedicine2024

Advancements in Betulinic Acid-Loaded Nanoformulations for Enhanced Anti-Tumor Therapy.

Ke Wang, Jinlu Shang, Chao Tao, Mingquan Huang, Daiqing Wei, Liuxuan Yang, Jing Yang, Qingze Fan, Qian Ding, Meiling Zhou

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Betulinic acid and obesity-related disorders.Frontiers in pharmacology · 2025
    Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ke Wang *Department of Pharmacy, the Affiliated Hospital, Southwest Medical University, Luzhou, People's Republic of China.ORCID 0009-0004-8692-303X
Jinlu Shang *Department of Pharmacy, West China Hospital Sichuan University Jintang Hospital, Chengdu, People's Republic of China.ORCID 0009-0008-2859-8055
Chao Tao *Department of Pharmacy, the Affiliated Hospital, Southwest Medical University, Luzhou, People's Republic of China.ORCID 0009-0003-8034-7492
Mingquan HuangSichuan Treatment Center for Gynaecologic and Breast Diseases (Breast Surgery), the Affiliated Hospital, Southwest Medical University, Luzhou, People's Republic of China.
Daiqing WeiDepartment of Orthopaedics, the Affiliated Hospital, Southwest Medical University, Luzhou, People's Republic of China.
Liuxuan YangDepartment of Pharmacy, the Affiliated Hospital, Southwest Medical University, Luzhou, People's Republic of China.ORCID 0009-0009-8521-6436
Jing YangDepartment of Pharmacy, the Affiliated Hospital, Southwest Medical University, Luzhou, People's Republic of China.
Qingze FanDepartment of Pharmacy, the Affiliated Hospital, Southwest Medical University, Luzhou, People's Republic of China.ORCID 0000-0002-3212-0002
Qian DingDepartment of Clinical Pharmacy, the Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, People's Republic of China.
Meiling ZhouDepartment of Pharmacy, the Affiliated Hospital, Southwest Medical University, Luzhou, People's Republic of China.ORCID 0000-0002-0559-2450

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Betulinic acid (BA) is a natural compound obtained from plant extracts and is known for its diverse pharmacological effects, including anti-tumor, antibacterial, anti-inflammatory, antiviral, and anti-atherosclerotic properties. Its potential in anti-tumor therapy has garnered considerable attention, particularly for the treatment of breast, lung, and liver cancers. However, the clinical utility of BA is greatly hindered by its poor water solubility, low bioavailability, and off-target toxicity. To address these issues, researchers have developed various BA-loaded nanoformulations, such as nanoparticles, liposomes, micelles, and nanofibers, aiming to improve its solubility and bioavailability, prolong plasma half-life, and enhance targeting ability, thereby augmenting its anti-cancer efficacy. In preparing this review, we conducted extensive searches in well-known databases, including PubMed, Web of Science, and ScienceDirect, using keywords like "betulinic acid", "nanoparticles", "drug delivery", "tumor", and "cancer", covering the literature from 2014 to 2024. The review provides a comprehensive overview of recent advancements in the application of BA-loaded nano-delivery systems for anti-tumor therapy and offers insights into their future development prospects.

Indexed as

Betulinic AcidNanoparticlesNeoplasmsPentacyclic TriterpenesTriterpenesAnimalsAntineoplastic AgentsBiological AvailabilityDrug CarriersDrug Delivery SystemsHumansLiposomesMicellesSolubilityAntineoplastic AgentsBetulinic AcidDrug CarriersLiposomesMicellesPentacyclic TriterpenesTriterpenesanti-tumorbetulinic acidbioavailabilitynanoformulationstargeting

Identifiers

PMID39748899
PMCPMC11694648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.